These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
409 related articles for article (PubMed ID: 29061511)
21. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth. Liu XQ; Xiong MH; Shu XT; Tang RZ; Wang J Mol Pharm; 2012 Oct; 9(10):2863-74. PubMed ID: 22924580 [TBL] [Abstract][Full Text] [Related]
22. Dual-targeted nano-in-nano albumin carriers enhance the efficacy of combined chemo/herbal therapy of lung cancer. Elgohary MM; Helmy MW; Mortada SM; Elzoghby AO Nanomedicine (Lond); 2018 Sep; 13(17):2221-2224. PubMed ID: 30265215 [TBL] [Abstract][Full Text] [Related]
23. Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice. Jin M; Hou Y; Quan X; Chen L; Gao Z; Huang W Int J Nanomedicine; 2021; 16():5479-5494. PubMed ID: 34413645 [TBL] [Abstract][Full Text] [Related]
24. Stimuli-responsive release and efficient siRNA delivery in non-small cell lung cancer by a poly(l-histidine)-based multifunctional nanoplatform. Shi M; Zhang J; Huang Z; Chen Y; Pan S; Hu H; Qiao M; Chen D; Zhao X J Mater Chem B; 2020 Feb; 8(8):1616-1628. PubMed ID: 32010914 [TBL] [Abstract][Full Text] [Related]
25. MicroRNA-4465 suppresses tumor proliferation and metastasis in non-small cell lung cancer by directly targeting the oncogene EZH2. Sun J; Tian X; Lu SQ; Hu HB Biomed Pharmacother; 2017 Dec; 96():1358-1362. PubMed ID: 29169732 [TBL] [Abstract][Full Text] [Related]
26. Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer. Yin T; Wang L; Yin L; Zhou J; Huo M Biomaterials; 2015 Aug; 61():10-25. PubMed ID: 25996409 [TBL] [Abstract][Full Text] [Related]
27. Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice. Luan X; Rahme K; Cong Z; Wang L; Zou Y; He Y; Yang H; Holmes JD; O'Driscoll CM; Guo J Eur J Pharm Biopharm; 2019 Apr; 137():56-67. PubMed ID: 30779980 [TBL] [Abstract][Full Text] [Related]
28. Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice. Wang XL; Xu R; Wu X; Gillespie D; Jensen R; Lu ZR Mol Pharm; 2009; 6(3):738-46. PubMed ID: 19296675 [TBL] [Abstract][Full Text] [Related]
29. Systemic delivery of siRNA by hyaluronan-functionalized calcium phosphate nanoparticles for tumor-targeted therapy. Qiu C; Wei W; Sun J; Zhang HT; Ding JS; Wang JC; Zhang Q Nanoscale; 2016 Jul; 8(26):13033-44. PubMed ID: 27314204 [TBL] [Abstract][Full Text] [Related]
30. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells. Song Y; Tang C; Yin C Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030 [TBL] [Abstract][Full Text] [Related]
31. Brain tumor-targeted therapy by systemic delivery of siRNA with Transferrin receptor-mediated core-shell nanoparticles. Wei L; Guo XY; Yang T; Yu MZ; Chen DW; Wang JC Int J Pharm; 2016 Aug; 510(1):394-405. PubMed ID: 27374198 [TBL] [Abstract][Full Text] [Related]
32. Inhibition against growth of glioblastoma multiforme in vitro using etoposide-loaded solid lipid nanoparticles with p-aminophenyl-α-D-manno-pyranoside and folic acid. Kuo YC; Lee CH J Pharm Sci; 2015 May; 104(5):1804-14. PubMed ID: 25694089 [TBL] [Abstract][Full Text] [Related]
33. Tumor-targeted pH/redox dual-sensitive unimolecular nanoparticles for efficient siRNA delivery. Chen G; Wang Y; Xie R; Gong S J Control Release; 2017 Aug; 259():105-114. PubMed ID: 28159516 [TBL] [Abstract][Full Text] [Related]
34. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy. He Y; Su Z; Xue L; Xu H; Zhang C J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977 [TBL] [Abstract][Full Text] [Related]
35. Dual Peptide-Modified Nanoparticles Improve Combination Chemotherapy of Etoposide and siPIK3CA Against Drug-Resistant Small Cell Lung Carcinoma. Huang HL; Lin WJ Pharmaceutics; 2020 Mar; 12(3):. PubMed ID: 32178266 [TBL] [Abstract][Full Text] [Related]
36. A synergistic approach for management of lung carcinoma through folic acid functionalized co-therapy of capsaicin and gefitinib nanoparticles: Enhanced apoptosis and metalloproteinase-9 down-regulation. Parashar P; Tripathi CB; Arya M; Kanoujia J; Singh M; Yadav A; Kaithwas G; Saraf SA Phytomedicine; 2019 Feb; 53():107-123. PubMed ID: 30668390 [TBL] [Abstract][Full Text] [Related]
37. Paclitaxel and etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma. Wang B; Yu XC; Xu SF; Xu M J Nanobiotechnology; 2015 Mar; 13():22. PubMed ID: 25880868 [TBL] [Abstract][Full Text] [Related]
38. Targeting delivery of etoposide to inhibit the growth of human glioblastoma multiforme using lactoferrin- and folic acid-grafted poly(lactide-co-glycolide) nanoparticles. Kuo YC; Chen YC Int J Pharm; 2015 Feb; 479(1):138-49. PubMed ID: 25560309 [TBL] [Abstract][Full Text] [Related]
39. pH sensitive nano layered double hydroxides reduce the hematotoxicity and enhance the anticancer efficacy of etoposide on non-small cell lung cancer. Zhu R; Wang Q; Zhu Y; Wang Z; Zhang H; Wu B; Wu X; Wang S Acta Biomater; 2016 Jan; 29():320-332. PubMed ID: 26485164 [TBL] [Abstract][Full Text] [Related]
40. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells. Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]